In last 15 years, pharmaceutical companies have spent hundreds of millions of dollars looking for a new transdermal delivery platform that delivers a broad range of drugs. Other than BioChemics’ VALE® technology, all technologies existing today deliver only 12-15 limited molecules.
All other transdermal
systems have functioned on the premise that only
the outer layer of skin needed to be penetrated for
transdermal delivery to occur. The logic was that,
if you could penetrate the stratum corneum and get
deep enough into the skin, access to the blood stream
(systemic delivery) would naturally occur. The premise
only worked for 12-15 drugs that have a high log
P value and molecular structure such that they can
penetrate skin structure on their own (nicotine,
testosterone, estrogen, fentanyl, dyclophanac, etc.),
while the balance of existing drugs did not penetrate
the skin at all.
VALE® technology has made a major advance by looking at other barrier structures (biochemical and biophysical) in the skin. Our scientists believed that the skin must have additional protective barriers designed to keep foreign substances out in addition to the stratum corneum as the skin is the largest organ and is designed to protect the body from intrusion. Our research has led to major advances in understanding the functionality of skin and subsequently the technology needed to create the first truly broad based, efficient transdermal technology.
The platform is currently composed of three technologies:
No other dug delivery company that exists today can come close to competing with BioChemics on its
platform technology capabilities and potential product pipeline.